MET and pulmonary arterial hypertension: For example, Nintedanib, a tyrosine kinase inhibitor of PDGF, FGF, and VEGF, has been shown to ameliorate pulmonary hypertension by blocking EndMT (Tsutsumi et al., 2019) and inhibitors of the HGF receptor c-Met (e.g., carbozantinib) are at present intensively explored in Ewing sarcoma and osteosarcoma clinical trials (Italiano et al., 2020).